Hemophilia A
Conditions
Brief summary
This study is a multi-center, open-label, extension trial to evaluate the safety, efficacy of SCT800 in long term prophylaxis and on-demand treatment in patients with severe hemophilia A who have been previously treated with coagulation factor VIII(FVIII) . This study includes two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of SCT800 shall be administered once every other day or three times per week starting from V1, on-demand treatment is given when bleeding episodes occur. The study period is 120 consecutive weeks.
Interventions
Participants received SCT800 for prophylaxis and/or on-demand treatment for 120 weeks.
Sponsors
Sinocelltech Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
* Male patients who are diagnosed with severe (laboratory tested FVIII:C \<2%) hemophilia A; * Patients Who Completed trial of SCT800-A302 or SCT800-A 303 and New PTP(previously treated patients)(Previously received FVIII prophylactic or bleeding treatment, have the relevant records and are verified to have accumulated exposures days( EDs) ≥150 days; * Negative FVIII inhibitor assay results (laboratory tested Nijmegen-Bethesda assay result \<0.6 BU(Bethesda unit)/mL); * The treatment records of at least 50EDs before screening can be obtained; * HIV negative; if HIV positive, the viral load \<200 particles/uL or \<400,000 copies/mL, and HIV patients must satisfy CD4+ count \>200/μL; * The patient or his guardian voluntarily signed the Informed Consent Form.
Exclusion criteria
* Known allergy to any coagulation factor VIII or any excipient; known allergy to bovine, rodent or hamster bovine; * Has a history or family history of blood coagulation factor VIII inhibitor; * Patients with other coagulation dysfunction diseases in addition to hemophilia A; * Patients with other clinically significant diseases, alcoholism, drug abuse, mental disorders or intellectual disabilities; * Patients with other severe or clinical significant diseases verified by the investigator to be unable to benefit from the clinical study; * Patients who participated in other clinical studies within one month before the first drug administration (except FVIII trials) and patients who participated in other FVIII clinical trials after signing the Informed Consent Form;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of FVIII inhibitors | up to 120 weeks | The Nijmegen-Bethesda assay shall be used to monitor the production of FVIII inhibitors during the trial. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Annualized Bleeding Rate | up to 120 weeks | Annualized Bleeding Rate（ABR） can be calculated using the following formula: Number of bleeding events in efficacy evaluation period/(number of days in treatment period/365.25) |
| FVIII incremental in-vivo recovery | up to 120 weeks | Incremental recovery is determined as the peak factor level recorded in the first hour after infusion and is reported as \[IU/ml\]/\[IU/kg\] |
| Bleeding event treatment efficacy | up to 120 weeks | The investigator shall evaluate the hemostatic effect after the treatment of every bleeding event of subjects based on a four-point scale(excellent, good, moderate, not relieved). |
Countries
China
Contacts
Primary ContactRenchi Yang
Backup ContactFeng Xu
Outcome results
None listed